BioDelivery Sciences (NasdaqCM: BDSI) is focused on the development and commercialization of novel treatments to address unmet needs within the pain and opioid dependence markets. The Company has developed a proprietary method of buccal film drug delivery, which it has utilized in two FDA approved products, Bunavail (buprenorphine and naloxone) for opioid addiction and Onsolis (fentanyl) for breakthrough cancer pain. BDSI is also using this technology to develop a chronic pain treatment, Belbuca (buprenorphine), for which the Company has an NDA currently under review. BDSI is commercializing Bunavail independently and has licensed Belbuca to Endo Pharmaceuticals (NasdaqGS: ENDP). The FDA has given a PDUFA action date for Belbuca of October 23, 2015.